Indazole-Based Liver X Receptor (LXR) Modulators with Maintained Atherosclerotic Lesion Reduction Activity but Diminished Stimulation of Hepatic Triglyceride Synthesis-Reference-Cited by-同舟云学术

Indazole-Based Liver X Receptor (LXR) Modulators with Maintained Atherosclerotic Lesion Reduction Activity but Diminished Stimulation of Hepatic Triglyceride Synthesis

Published:2008-10-31 Issue:22 Volume:51 Page:7161-7168
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wrobel Jay¹,Steffan Robert¹,Bowen S. Marc¹,Magolda Ronald¹,Matelan Edward¹,Unwalla Rayomand¹,Basso Michael¹,Clerin Valerie¹,Gardell Stephen J.¹,Nambi Ponnal¹,Quinet Elaine¹,Reminick Jason I.¹,Vlasuk George P.¹,Wang Shuguang¹,Feingold Irene¹,Huselton Christine¹,Bonn Tomas¹,Farnegardh Mathias¹,Hansson Tomas¹,Nilsson Annika Goos¹,Wilhelmsson Anna¹,Zamaratski Edouard¹,Evans Mark J.¹

Affiliation:

1. Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm800799q

Reference24 articles.

1. LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism

2. Nuclear Receptors in Lipid Metabolism: Targeting the Heart of Dyslipidemia

3. The Pharmacology of LXR

4. Identification of macrophage liver X receptors as inhibitors of atherosclerosis

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonlipogenic ABCA1 Inducers (NLAI) for Alzheimer’s Disease Validated in a Mouse Model Expressing Human APOE3/APOE4;Journal of Medicinal Chemistry;2024-08-27

2. Chemogenomics for NR1 nuclear hormone receptors;Nature Communications;2024-06-18

3. Rhodium‐Catalysed Selective C−H Allylation of 1H‐Indazoles with Vinylethylene Carbonate: Easily Introducing Allylic Alcohol;European Journal of Organic Chemistry;2023-09-25

4. GNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1;Journal of Medicinal Chemistry;2023-09-13

5. Development of Light‐Activated LXR Agonists;ChemMedChem;2023-06